Rolfe Lindsey 4
4 · Clovis Oncology, Inc. · Filed Aug 3, 2022
Insider Transaction Report
Form 4
Rolfe Lindsey
See Remarks
Transactions
- Sale
Common Stock
2022-08-02$1.46/sh−1,939$2,833→ 104,826 total - Exercise/Conversion
Restricted Stock Units
2022-08-01−3,749→ 7,499 total→ Common Stock (3,749 underlying) - Exercise/Conversion
Restricted Stock Units
2022-08-01−4,625→ 27,750 total→ Common Stock (4,625 underlying) - Exercise/Conversion
Common Stock
2022-08-01+3,749→ 106,765 total - Sale
Common Stock
2022-08-02$1.46/sh−2,391$3,493→ 107,060 total - Exercise/Conversion
Common Stock
2022-08-01+4,625→ 109,451 total
Footnotes (5)
- [F1]Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- [F2]Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
- [F3]This transaction was executed in multiple trades at prices ranging from $ 1.4600 to $1.4947. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
- [F5]On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.